Results 161 to 170 of about 29,485 (291)

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH‐AHA‐EMI Study

Haemophilia, EarlyView.
ABSTRACT Introduction The GTH‐AHA‐EMI study showed that emicizumab reduces bleeding in patients with acquired haemophilia A (AHA). However, 22 clinically relevant new bleeds (CRNB) occurred in 14 of the 47 study patients, most of which required haemostatic treatment.
Halet Türkantoz, Christiane Dobbelstein, Richard Greil, Christina Hart, Robert Klamroth, Paul Knöbl, Johannes Oldenburg, Christian Pfrepper, Ulrich Sachs, Inga M. Schimansky, Karolin Trautmann‐Grill, Andreas Tiede   +11 more
wiley   +1 more source

Physical Activity and Sedentary Behaviour in Children With Haemophilia

Haemophilia, EarlyView.
ABSTRACT Introduction Physical activity (PA) is vital in child development, while inactivity remains a leading contributor to global mortality. Therapeutic advances have enabled greater PA in boys with haemophilia (BwH), yet robust UK data on objectively measured PA and sedentary behaviour (SB) across severities are limited.
Melanie Bladen, Lucy Alderson, Eleanor Main, Mario Cortina‐Borja   +3 more
wiley   +1 more source

Infections after bispecific antibodies in B-cell lymphomas. [PDF]

Blood Adv
Kim DH, Lee N, Koh Y, Jo HJ, Kang CK, Choe PG, Park WB, Lee CM, Byun JM, Kim NJ.   +9 more
europepmc   +1 more source

Consistency of c‐Met protein overexpression over time in patients with non‐squamous non‐small cell lung cancer

Histopathology, EarlyView.
c‐Met protein overexpression can be assessed before or after treatment in patients with non‐squamous NSCLC since most patients maintain a consistent c‐Met status. However, as targeted therapies may elevate c‐Met overexpression, retesting may be necessary for subsets of patients.
Alexis B Cortot, Romain Dubois, Valérie Grégoire, Jean‐Baptiste Gibier, Julien Labreuche, Virginie Deprez, Déborah Dubrulle, Thomas Chretien, Eric Wasielewski, Hélène Behal, Dai Feng, Amber Lind, Peter Ansell, Raphaële Thiébaut‐Millot, Carlos Hader   +14 more
wiley   +1 more source

Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma. [PDF]

Blood Cancer J
Chohan KL, Welkie RL, Godfrey J, Bair S, Falchi L, Kamdar M, Major A, Dixon W, Crombie J, Merryman R, Godbole S, Salles G, Farahat O, Ayers A, Chauhan A, Herrera A, Shouse G, Ahmed S, Sawalha Y.   +18 more
europepmc   +1 more source

Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma. [PDF]

Cells
Maher N, Al Deeban B, Diop NM, Assaf J, Moia R, Mouhssine S, Gaidano G.   +6 more
europepmc   +1 more source

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran, Matjaž Fležar, Manuel Pedro Pereira   +2 more
wiley   +1 more source

Bispecific antibodies and nanotechnology: a strategic alliance in cancer immunotherapy. [PDF]

Mol Cancer
Battistini E, Lapuhs P, Jiménez A, Garrido-Areal S, Rivas-Gómez L, Zagorac I, Álvarez-Vallina L, Alonso MJ, Sanjurjo L.   +8 more
europepmc   +1 more source

Toxoplasmosis Beyond Transplantation: Diagnostic and Prevention Challenges in a Patient Receiving Targeted Immunomodulators

Transplant Infectious Disease, EarlyView.
ABSTRACT Toxoplasmosis has long been recognized as a serious complication in immunocompromised host, particularly those with advanced HIV/AIDS, hematopoietic stem‐cell transplantation (HSCT), solid‐organ transplant (SOT), and hematological malignancies. The rapid expansion of targeted immunomodulators, including chimeric antigen receptor T‐cell (CAR‐T)
Joy Mouanes‐Abelin, Christelle Pomares, José G. Montoya, Morgane Pondrom, Lucille DE MARIA, Andrea J. Zimmer, Carlos A. Gomez   +6 more
wiley   +1 more source

Tumor-targeted bispecific antibodies effectively inhibit oncogenic pathways while minimizing toxicity. [PDF]

Sci Adv
Kschonsak YT, Liang WC, Chan J, Kan D, Nguyen T, Ruiz K, Kee YS, Tsai WK, Xi H, Moskalenko M, Morgenstern T, Herault A, Cabon L, Okuda R, Stawicki SS, Chan J, Grimmer M, Ellerman D, Mondo J, Ruff CF, Schaefer G, Segal U, Piskol R, Agard NJ, Comps-Agrar L, de Sousa E Melo F, Koerber JT.   +26 more
europepmc   +1 more source